Vaccinex

Rank#11125

Market Cap2.81M

CountryUnited States

Summary

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

History

Vaccinex was founded in 2001 as a vaccines company with a focus on developing novel products to fight cancer and other life-threatening diseases. The company swiftly shifted its focus to innovative therapeutics and cutting-edge scientific research, leading to its first breakthrough product, Vaximmune®, which is currently in clinical trials for treating prostate cancer.

Mission

At Vaccinex, our mission is to improve the lives of patients through generating transformative science-driven therapies. Our efforts are focused on creating treatments that reduce suffering caused by disease and extend the quality of life of patients and their families.

Vision

Vaccinex’s vision is to improve the health and well-being of people throughout the world by continuously innovating, developing, commercializing and implementing clinical-stage therapeutic programs.

References

https://in.investing.com/equities/vaccinex-inc

https://finance.yahoo.com/quote/VCNX/profile?p=VCNX

https://www.crunchbase.com/organization/vaccinex

https://companiesmarketcap.com/

https://www.vaccinex.com

Leadership team

Dr. Maurice Zauderer Ph.D. (Co-Founder, CEO, Pres & Director)

Mr. Scott E. Royer C.F.A., M.B.A. (Chief Financial Officer)

Dr. Ernest S. Smith Ph.D. (Sr. VP of Research & Chief Scientific Officer)

Products / Services

Biotechnology, Clinical Trials, Health Care